This is particularly important given that GLP-1 medications often involve dose adjustments, side effect management, shifts in appetite behaviour, and occasional plateaus that benefit from structured clinical reassurance
GLP-1 medications increase nausea and vomiting risk, which can lead to dehydration and acute kidney injury in those with compromised renal function
Lancet 2004;364:1789-1799 Kennedy S, Bergqvist A, Charon C, et al
However, with the aspects of these new mass obesity medications, the microenvironment, the genetic environment, and lifestyle and behavior change is especially difficult for these patients to lose weight and maintain it, and we also know that, from SURMOUNT trials and some real-world evidence, that tirzepatide is extremely effective at encouraging significant weight loss. Huang and colleagues conducted a retrospective cohort study of 4,241 women living with PCOS (median age, 34 years